A study examining the perspective of patients recently diagnosed with prostate cancer has revealed that patients may be willing to relinquish some survival probability in order to avoid side-effects and repeat treatments.
Browsing: Disease Area > Prostate
Johnson & Johnson have recently announced that the District court of New Jersey has issued a ruling that invalidates claims to the prostate cancer drug ZYTIGA® (abiraterone acetate).
A team of researchers have created a method of measuring how circulating tumor cells perform functions that drive cancer, such as producing matrix metalloproteases.
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Researchers have developed a quicker and more accurate way of testing new prostate cancer treatments.
A test that is able to detect trace levels of circulating tumor cells could help spot the early signs of treatment not working for advanced prostate cancer patients.
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.